DEVA "Doktor, Eczacı ve Alatları" (Physicians, Pharmacists and Diagnostics) Sanayi ve Ticaret A.Ş. was incorporated.
The first manufacturing facility is established in Tünel, Beyoğlu.
Bomonti pharmaceutical plant was opened.
The ampoule plant was set up.
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey. The title and status of the Company was changed from DEVA "Doktorlar Ecza ve Alat" (Physicians Drugs and Equipment) Sanayi ve Ticaret Anonim Şirketi to DEVA Holding A.Ş.
The largest pharmaceutical manufacturing facility was purchased from Farmitalia.
Carlo Erba pharmaceutical plant was purchased.
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was listed among 5 establishments to produce this active ingredient throughout the world.
A detergent and cologne factory was set up in İzmit.
DEVA Holding A.Ş.'nin sermayesi'nin 1 milyar TL'ye çıkartıldı ve ortak sayısı 6.000 kişiye ulaştı.
The shares of DEVA Holding started to be traded on the Istanbul Stock Exchange.
The production of lincomycin (antibiotic) was started at the "pharmaceutical active ingredient" manufacturing facilities.
The foundation of the synthesis plant were laid in Çerkezköy.
ANSA A.Ş. was purchased by DEVA Holding, the title of the firm was changed as DEPA A.Ş. With the production of Potassium Clavulanate, the company accomplished being one of only five establishments in the world capable of producing this active ingredient.
DEVA Holding A.Ş.'nin sermayesi 4 trilyon TL'ye çıkartıldı ve ortak sayısı 15.000 kişiye ulaştı.
DEVA Holding ranked among the top 10 pharmaceutical companies of Turkey with USD 120 million sales on box basis and a market share of 4,6%. The equity capital of the company was increased to TRY 48 million. Amoklavin became the best selling drug of the year in Turkey.
The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit. Representative offices were opened in Georgia, Russia (Moscow), Azerbaijan and Uzbekistan.
50 years of success in the sector was celebrated together with doctors and pharmacists all around Turkey.
Inhaler manufacturing site opened. FDA ANDA submission 107 approval in 19 countries inc. Germany, Switzerland, Holland, Australia, New Zeland